Skip to main content

Table 6 Summary of trials addressing systemic therapy in advanced breast cancer

From: Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer

Author, year

Institution(s)/ Database

Population

Time intervals

Comments

Andre, 2004 [5]

France (3 institutions)

724 women de novo metastatic breast cancer

1987-1993

Excluded supraclavicular lymph node only patients. Improved 3 year overall survival (OS; 44% vs 27%) was seen in the more recent time period.

   

1994-2000

 

Giordano, 2004 [9]

MD Anderson Cancer Center

834 women with recurrence after adjuvant doxorubicin

1974-1979

Included patients with locally recurrent disease. Predictors of improved overall survival included stage at diagnosis, interval disease-free survival, and dominant metastatic site.

   

1980-1984

 
   

1985-1989

 
   

1990-1994

 
   

1995-2000

 

Chia, 2007 [6]

British Columbia Cancer Agency

2150 women with both recurrent and de novo metastatic breast cancer

1991-1992

An improvement in overall survival was noted over time, primarily in those patients that were hormone-receptor positive.

   

1994-1995

 
   

1997-1998

 
   

1999-2001

 

Dawood, 2008 [13]

Surveillance, Epidemiology, and End Results Registry

15,438 women with both recurrent and de novo metastatic breast cancer

1988-1993

There was a modest improvement in overall survival, associated with patients with hormone-receptor positive disease. Outcomes appeared to be worse in African American women.

   

1994-1998

 
   

1999-2002

 
   

2003-2006

 

Dafni, 2009 [14]

Hellenic Cooperative Group

1361 enrolled on trials for treatment of recurrent and de novo metastatic breast cancer

1991-1994

Trastuzumab used in 24% and 30% of patients in the two most recent time intervals.

   

1995-1998

 
   

1999-2003

 

Ruiterkamp, 2011 [10]

Netherlands

8031 women with both recurrent and de novo metastatic breast cancer

1995-1999

10% of patients in third time interval received targeted therapy.

   

2000-2004

 
   

2005-2008

 

Pal, 2011

City of Hope

274 de novo metastatic breast cancer only

1985-1994

Overall survival improved for those receiving endocrine therapy, but no apparent overall survival benefit with newer chemotherapeutic agents.

   

1995-2004

Â